Skip to main content

Table 2 Univariate Cox regression analysis for 30-day mortality

From: Copeptin and risk stratification in patients with acute dyspnea

 

All patients

ADHF

No ADHF

Characteristic

HR for 30-day mortality

P -value

HR for 30-day mortality

P -value

HR for 30-day mortality

P -value

Age (yr)

1.05 (1.01 to 1.10)

0.012

1.03 (0.98 to 1.09)

0.230

1.06 (0.99 to 1.13)

0.1

Male sex

1.55 (0.73 to 3.27)

0.255

1.59 (0.66 to 3.84)

0.300

1.51 (0.36 to 6.33)

0.57

BMI

0.99 (0.93 to 1.05)

0.68

1.01 (0.94 to 1.08)

0.830

0.91 (0.80 to 1.04)

0.18

Medical conditions (% of patients)

      

   Heart failure

1.40 (0.64 to 3.08)

0.4

1.13 (0.48 to 2.69)

0.780

0.05 (0.00 to 7228)

0.61

   Coronary artery disease

0.52 (0.20 to 1.35)

0.18

0.47 (0.17 to 1.29)

0.140

0.04 (0.00 to 127)

0.43

   Chronic obstructive pulmonary disease

0.47 (0.33 to 1.68)

0.48

1.12 (0.44 to 2.89)

0.810

0.46 (0.09 to 2.26)

0.34

   Diabetes

0.72 (0.25 to 2.06)

0.53

0.50 (0.15 to 1.70)

0.270

1.16 (0.14 to 9.40)

0.89

   Hypertension

0.77 (0.36 to 1.62)

0.49

0.52 (0.21 to 1.28)

0.150

0.80 (0.20 to 3.20)

0.75

   Hyperlipidemia

0.37 (0.13 to 1.06)

0.07

0.32 (0.10 to 1.09)

0.070

0.41 (0.05 to 3.34)

0.41

   Chronic kidney disease

2.89 (1.39 to 5.98)

0.004

1.47 (0.62 to 3.46)

0.380

9.64 (2.41 to 38.61)

0.001

Initial clinical findings

      

   Heart rate (bpm)

1.01 (0.99 to 1.02)

0.45

1.00 (0.98 to 1.02)

0.870

1.02 (0.99 to 1.05)

0.22

   Systolic pressure (mm Hg)

0.97 (0.96 to 0.99)

< 0.001

0.98 (0.96 to 0.99)

0.010

0.97 (0.94 to 1.00)

0.02

   NYHA functional class

3.44 (1.74 to 6.81)

< 0.001

7.47 (2.28 to 24.45)

0.001

1.53 (0.65 to 3.67)

0.33

   Edema

1.73 (0.83 to 3.59)

0.14

1.02 (0.43 to 2.42)

0.960

3.00 (0.75 to 12.00)

0.12

   Rales

1.40 (0.66 to 2.95)

0.38

0.72 (0.30 to 1.74)

0.460

4.14 (0.84 to 20.53)

0.08

Medication at admission

      

   Beta-blockers

0.82 (0.38 to 1.76)

0.61

0.65 (0.28 to 1.53)

0.320

0.04 (0.00 to 90)

0.41

   ACE-Inhibitors/AT-receptor-blockers

0.95 (0.46 to 1.96)

0.88

0.51(0.22 to 1.20)

0.120

1.96 (0.49 to 7.85)

0.34

   Diuretics

1.76 (0.82 to 3.79)

0.15

1.40 (0.54 to 3.60)

0.490

1.62 (0.41 to 6.49)

0.49

Laboratory findings

      

   eGFR - ml/minute/1.73m2 a

0.11 (0.04 to 0.35)

< 0.001

0.18 (0.04 to 0.81)

0.025

0.08 (0.01 to 0.55)

0.011

   BNP a

2.02 (1.14 to 3.58)

0.017

1.23 (0.44 to 3.41)

0.700

3.66 (0.83 to 16.11)

0.086

   NT-proBNP a

3.64 (2.02 to 6.56)

< 0.0001

4.57 (1.72 to 12.17)

0.002

8.26 (2.34 to 29.12)

0.001

   Copeptin a

5.28 (3.08 to 9.06)

< 0.0001

5.36 (2.82 to 10.19)

< 0.001

4.21 (1.46 to 12.14)

0.008

  1. a log-transformed to achieve normal distribution.
  2. BMI, body mass index; eGRF, estimated glomerular filtration rate; NYHA, New York Heart Association; BNP, B-type natriuretic peptide; NT-proBNP, N-terminal pro-B-type natriuretic peptide.